Nevro (NYSE:NVRO) today touted results from a trial of its Senza system for treating painful diabetic neuropathy (PDN)-related chronic pain.
Redwood City, Calif.-based Nevro, which published the results of the SENZA-PDN trial in JAMA Neurology, said in a news release that, if approved, the Senza spinal cord stimulation (SCS) system would be the first FDA-approved SCS system with a specific on-label indication for treating PDN.
Get the full story at our sister site, Drug Delivery Business News.
The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out.
Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world in infections, accounting for 28.4 million cases. More than 2.5 million people have died from the virus globally. Medtech has been on the frontlines throughout the pandemic, whether it was shifting production to make ventilators or PPE or developing COVID-19 tests and vaccines.
More than a year since the virus’ appearance in the U.S., some medtech CEOs are gaining a better understanding of how the industry may look moving forward. From stockpiling to new COVID-19 variants posing risks, here are the insights from seven CEOs.
Next >>[Photo by Fusion Medical Animation on Unsplash]
The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out.Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world in infections, accounting for 28.4 million cases. More than 2.5 million people have died from the virus globally. Medtech has been on the frontlines throughout the pandemic, whether it was shifting production to make ventilators or PPE or developing COVID-19 tests and vaccines.
More than a year since the virus’ appearance in the U.S., some medtech CEOs are gaining a better understanding of how the industry may look moving forward. From stockpiling to new COVID-19 variants posing risks, here are the insights from s…
Nevro (NYSE:NVRO) posted fourth-quarter results that beat the consensus forecast on Wall Street as it issued 2021 guidance that was slightly below analysts’ expectations.
The Redwood City, Calif.–based spinal cord stimulation system maker reported a loss of –$7.2 million, or –21¢ per share, on sales of $109.7 million for the three months ended Dec. 31, 2020, versus a loss of –$13.5 million, or –44¢ per share, on sales of $114.3 million in Q4 2019.
The results beat the expectations of The Street, where analysts on average predicted a loss of –33¢ per share on sales of $107.4 million.
“Both U.S. and international revenue was meaningfully impacted by the resurgence of COVID activity in the second half of the quarter,” CEO D. Keith Grossman said during an earnings call yesterday evening.
Grossman later added: “I really believe we’re well-positioned for attractive and sustainable growth as the pressure of COVID on our busi…
Nevro (NYSE:NVRO) announced today that it appointed Roderick MacLeod as its new chief financial officer, effective June 15.
MacLeod will succeed current CFO Andrew Galligan, who is set to retire, but will remain on with the company during a transition period as MacLeod takes over. Galligan spent 10 years at Nevro, according to a news release.
“I’m very pleased to join Nevro and I view this as an exciting opportunity to continue to build a great company while helping patients who suffer from chronic pain,” MacLeod said in the release. “I look forward to working closely with Keith and the rest of the Nevro team to execute on the Company’s growth strategy.”
Prior to taking on this new role, the 25-year veteran of financial and executive leadership roles in healthcare and technology spent 16 years at Stryker (NYSE:SYK). He served as VP of finance at Stryker Endoscopy and, before that, controller for the same division. Mac…